

The views expressed in this document are the views of the author/s and do not necessarily reflect the views or policies of the Asian Development Bank, or its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy of the data included in this presentation and accepts no responsibility for any consequence of their use. The countries listed in this presentation do not imply any view of ADB's part as to sovereignty or independent status or necessarily conform to ADB's terminology.

# Rolling Out the COVID-19 Vaccines

Eduardo Banzon

13<sup>th</sup> PACER Dialogue

<b>Countries (as of 19 Feb 2021)</b>	<b>Total number of COVID19 doses administered</b>	<b>Number of doses administered per 100 people</b>	<b>Daily rate of doses administered</b>
Palau	5,314	29.29	212
Maldives	64,048	17.22	5,532
Marshall Islands (RMI)	6,760	11.42	190
Singapore	256,000	4.49	9,375
PRC	40,500,000	2.89	1,550,000
Micronesia (FSM)	11,119	2.01	394
Bangladesh	1,848,313	1.11	215,792
Sri Lanka	196,163	0.9	4,881
India	9,846,523	0.72	404,201
Indonesia	1,787,976	0.67	60,741
Azerbaijan	65,000	0.64	
Nepal	158,487	0.56	6,322
Myanmar	103,561	0.2	32
Kazakhstan	16,801	0.09	–
Pakistan	52,768	0.03	–
Cambodia	3,803	0.02	–
Japan	611	0	-


Countries (as of 19 Feb 2021)	Total number of COVID19 doses administered	Number of doses administered per 100 people	Daily rate of doses administered
Global	193,291,612	–	4,854,819
U.S.	59,082,379	17.8	1,579,005
PRC	40,500,000	2.89	1,550,000
U.K.	16,996,806	25.45	<b>423,322</b>
India	9,846,523	0.72	404,201
Israel	7,065,195	78.06	129,818
Brazil	6,218,769	2.96	234,456
Turkey	6,155,541	7.4	<b>440,785</b>
United Arab Emirates	5,373,730	49.99	83,075
Germany	4,572,420	5.5	129,039
France	3,329,201	5.14	118,038
Italy	3,279,129	5.43	64,536
Spain	2,782,751	5.99	66,035
Poland	2,384,794	6.28	71,526
Chile	2,375,725	12.43	<b>152,528</b>
Morocco	2,233,123	6.28	196,829
Russia	2,200,000	1.5	35,000
Bangladesh	1,848,313	1.11	215,792
Indonesia	1,787,976	0.67	60,741

# What made COVID-19 vaccines available?

Country	Vaccines
Azerbaijan	Oxford/AstraZeneca, Sputnik V
Bangladesh	Oxford/AstraZeneca from SII
Cambodia	Sinopharm/Beijing
PRC	Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac
India	Covaxin, Oxford/AstraZeneca from SII
Indonesia	Sinovac
Japan	Pfizer/BioNTech
Maldives	Oxford/AstraZeneca from SII
Myanmar	Oxford/AstraZeneca from SII
Nepal	Oxford/AstraZeneca from SII
Pakistan	Sinopharm/Beijing
Singapore	Pfizer/BioNTech



**Vaccine Manufacturing + Donations**  
(Regional Cooperation)



**Bilateral Deals**



# Small populations and islands



**PLANS**

**MESSAGES**

**PRIVATE SECTOR**

**PEOPLE**

**LOCAL  
GOVERNMENTS**

**LOGISTICS**

**WHOLE of  
SOCIETY**

**WHOLE of  
GOVERNMENT**



# Asia Pacific Vaccine Access Facility (APVAX)



A **\$9 billion** facility to finance access and delivery of COVID19 vaccines in ADB's DMCs

- Builds on ADB's \$20 B **Comprehensive Response to the COVID-19 Pandemic** composed of CPRO loans and grants, health sector loans and grants, APDRF grants, TAs, and other support to DMCs

**APVAX will provide rapid support** to DMCs through loans or grants (for eligible countries) as they procure and deliver COVID-19 vaccines in a safe and effective manner.

- APVAX will employ **fast-tracked business processes**

## Access criteria

- demonstrated **adverse impact** (e.g., social, health, or economic, or a combination of them) of the COVID-19 pandemic;
- completion of **needs assessment** acceptable to ADB and a national **vaccination allocation plan** that indicates prioritization of vaccine access consistent with international norms and safeguards against exclusion of marginalized and vulnerable groups; and
- the presence of an **effective development partner coordination mechanism** and a clear role for ADB within this platform.

# APVAX Components

## Rapid Response Component (RRC) →



### Timely and focused financing

for vaccine access in the areas of vaccine procurement and logistics costs



### Diagnostic and analytical work

to prepare for vaccinations, payments to COVAX, procurement of vaccines, and logistics related to bringing vaccines from place of purchase to the DMC



### Advance financing

for quick disbursing support, streamlined project documentation and balanced due diligence

## Project Investment Component (PIC)



### Systems

for distribution, delivery, and administration of vaccines



### Physical infrastructure

for vaccine delivery and distribution (cold-chain storage and transportation, vehicles, processing facilities)



### Vaccine manufacturing capacity

(expansion or establishment)



### Training and capacity support

for health workers, public communications and outreach, surveillance systems to monitor and track implementation progress

## Eligible RRC Expenditure Items

Analytical/diagnostic work and policy development

International logistics and related services

Indirect management fees as required by the UN agencies

Vaccines acquired through COVAX

Vaccines from manufacturers that meet any of the eligibility requirements, including advance payments

## APVAX Vaccine Eligibility\*

Vaccine selected for procurement through COVAX on behalf of its participating countries;\* or

Vaccine manufacturer is prequalified by WHO; or

Vaccine is authorized by a stringent regulatory authority (SRA) for manufacture in an SRA country or the SRA has authorized its manufacture in a non-SRA country

*\* vaccines must have been authorized for use by the DMC's relevant national regulatory authority.*



## **Planned APVAX Loans with ongoing/ planned Technical Assistance on various aspects including regional cooperation**

- **Cambodia**
- **Indonesia**
- **Philippines**
  
- **Outside Southeast Asia (Planned APVAX Loans or Grants +TA)**
  - Pacific (Samoa, Tonga, Tuvalu and Vanuatu)
  - Mongolia
  - Afghanistan and Tajikistan
  - South Asian countries
  
- **More to come as countries are seeing the value of external financing to support vaccine roll-out**